Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.
|Published (Last):||5 September 2007|
|PDF File Size:||9.51 Mb|
|ePub File Size:||18.77 Mb|
|Price:||Free* [*Free Regsitration Required]|
This finding needs to be confirmed in a well-controlled study recimbinante a larger sample size. We reombinante confirm the completeness, accuracy and currency of the content. By clicking Subscribe, I agree to the Drugs. The values of C max and t max are comparable to those found by other authors, taking into account the above mentioned differences in methodology. Population pharmacokinetics of darbepoetin alfa in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration.
Nonerythropoietin receptor-mediated pathways may play a major role. The originating document has been archived.
Eritropoyetina Humana Recombinante –
Faculty of Pharmacy, University of Belgrade, Serbia. Among the remaining 96 patients 40 BEN and 56 others who met inclusion criteria, 10 with BEN and 14 with other kidney diseases were selected using systematic sampling i.
The enigma of the metabolic fate of circulating erythropoietin Epo in recomvinante of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Predialysis serum creatinine and PTH concentrations were significantly lower, and serum calcium concentration was significantly higher in the BEN than in the non-BEN group. Although basal plasma Epo concentration was similar in BEN Similar inter-individual differences were found in time needed to reach Epo C max.
Results The study involved 24 hemodialysis patients, 10 patients with BEN and 14 with other kidney diseases, selected from 96 patients 40 BEN and 56 others who erittopoyetina the inclusion criteria.
No significant differences between groups were found in maximal Epo concentration, time to maximum Eritroppoyetina concentration, area under the curve from time of dosing extrapolated to infinity, clearance, mean residence time of Epo between groups both before and after adjustment.
Pharmacokinetic analysis of beta-erythropoietin detected a significantly longer elimination half-life in BEN than in non BEN patients.
Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: The pharmacokinetic parameters of Epo are presented in Table 3. Comparison of the pharmacokinetics of beta-erythropoietin given subcutaneously to hemodialysis patients with BEN or other kidney diseases non-BEN. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
N Engl J Med ; As the main organs involved in Epo elimination are the kidneys and bone marrow and both kidney function and bone marrow cellularity decrease with age, the authors suggested that age and creatinine influence Epo elimination. A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection.
Eritropoyetina Humana Recombinante
Pavlovic-Kentera V, Djukanovic Lj. To view content sources and attributions, please refer to our editorial policy.
The prospective clinical study was performed according to good clinical practice and in accordance with the Declaration of Helsinki in three clinical centers.
It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Clin J Am Soc Nephrol ;1: Higher dose of erythropoietin recombinanfe anemia correction in Balkan endemic nephropathy patients. Colombia Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your eritropyetina circumstances.
Endemic Balkan Nephropathy, Proc. Pharmacokinetic analysis of subcutaneous humzna administration with nonlinear mixed effect model including endogenous production. Results of laboratory analyses in the examined individuals are given in Table 2.
This work was conducted as a part of projects No and funded by the Ministry of Science, Education and Technological Development, Belgrade, Republic of Serbia. Methods Study design and patients The prospective clinical study was performed according to good clinical practice and in accordance with the Declaration of Helsinki in three clinical centers.
Eritropoyetina Humana Recombinante Delta –
Der Mechanismus der Anaemie bie der endemische Nephropathie. Ciba Foundation Study Group No.
Eur J Clin Pharmacol ; The authors declare that they have no conflicts of interest related to the contents of this article.
This means it is still under development and may contain inaccuracies. Ingredient matches for Eritropoyetina Humana Recombinante Delta Erythropoietin Erythropoietin is reported as an ingredient of Eritropoyetina Humana Recombinante Delta in the following countries: The results were expressed as mean values with standard deviations.
Clin J Am Soc Nephrol ;3: Anaemia in Balkan endemic nephropathy. Subscribe to receive email notifications whenever new articles are published. Beta-erythropoietin administration and blood sampling.